RT Journal Article SR Electronic T1 Combination Therapy With S-1, Oxaliplatin and Leucovorin in Patients With Advanced Esophageal Squamous Cell Carcinoma JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 2249 OP 2254 DO 10.21873/invivo.11730 VO 33 IS 6 A1 NAOHIRO NISHIDA A1 MAKOTO YAMSAKI A1 KAZUKI ODAGIRI A1 KOTARO YAMASHITA A1 KOJI TANAKA A1 DAISUKE SAKAI A1 TOMOKI MAKINO A1 TSUYOSHI TAKAHASHI A1 YUKINORI KUROKAWA A1 TAROH SATOH A1 MASAKI MORI A1 YUICHIRO DOKI YR 2019 UL http://iv.iiarjournals.org/content/33/6/2249.abstract AB Background/Aim: In this study, we assessed the safety and efficacy of combination therapy with S-1, oxaliplatin and leucovorin (SOL) in advanced esophageal squamous cell carcinoma (ESCC) patients. Patients and Methods: Ten unresectable or recurrence ESCC patients, who had been previously treated with more than two regimens were included in this study. The treatment schedule comprised S-1 40-60 mg and fixed dose of leucovorin 25 mg together orally twice a day for one week, followed by one-week of rest. Oxaliplatin 85 mg/m2 was given as an intravenous infusion on day one, repeated every two weeks. Results: Of the eight patients with measurable lesions, two patients with partial response (25%) and two with stable disease (25%) were observed. Disease control rate was 50%. Median progression-free survival and overall survival were 5.0 and 9.3 months, respectively. The main common adverse events were malaise (60%), decreased appetite (50%), peripheral sensory neuropathy (40%). Conclusion: SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC.